cas 1571103-88-2|| where to buy 12,15-Dioxa-2,7,9-triazaheptadecanamide, 17-amino-N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-8-oxo-, hydrochloride (1:2)

Product Name:12,15-Dioxa-2,7,9-triazaheptadecanamide, 17-amino-N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-8-oxo-, hydrochloride (1:2)

IUPAC Name:3-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-1-{4-[({2-[2-(2-aminoethoxy)ethoxy]ethyl}carbamoyl)amino]butyl}urea dihydrochloride

: CAS：1571103-88-2; Molecular Formula：C18H42Cl2N6O6; Purity：95%+

Packing Unit	Available Stock	Price($)
CM454250-100mg	in stock	ȃƈ
CM454250-250mg	in stock	ƈƈŗ
CM454250-1g	in stock	ǙǪƥ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

: CAS NO:1571103-88-2; Molecular Formula:C18H42Cl2N6O6; Melting Point:-; Smiles Code:Cl.Cl.NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCN; Density:

: Catalog Number:CM454250; Molecular Weight:509.47; Boiling Point:; MDL No:MFCD29035188; Storage:

: Tenapanor; FDA has approved XPHOZAH (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

XPHOZAH, with its unique blocking mechanism of action, acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), reducing phosphate absorption through the paracellular pathway, the primary pathway of phosphate absorption.